Pancreatic Cancer News & Articles

News

In this weeks news:

• “Pancreas In A Dish” Will Show How Pancreatic Cancer Forms
  A tiny, living 3-D organ model of pancreatic ducts has been created by researchers in Toronto to help them understand pancreatic cancer, which is one of the deadliest yet least understood of all cancers. This new model could lead to the discovery of new ways to detect and treat pancreatic cancer.
• Amgen pancreatic cancer drug lacks efficacy, trial ends – chicagotribune.com
  Amgen Inc halted a late-stage trial of an experimental drug for pancreatic cancer after independent reviewers concluded that it was unlikely to significantly help patients.Amgen said the trial of ganitumab, also known as AMG479, did not raise any safety concerns. The company said it would also stop a separate mid-stage trial of the drug.
• High dietary antioxidant intake might cut pancreatic cancer risk
  Increasing dietary intake of the antioxidant vitamins C, E, and selenium could help cut the risk of developing pancreatic cancer by up to two thirds, suggests research published online in the journal Gut.
• Vitamin cuts deadly pancreatic cancer risk by half
• Trovagene to Study Trans-Renal KRAS Mutation Detection in Pancreatic Cancer – PR Newswire – The Sacramento Bee
  Trovagene, Inc. (Nasdaq: TROV), a developer of trans-renal molecular diagnostics, announced today that they will be collaborating with The University of Texas MD Anderson Cancer Center on the detection of transrenal KRAS mutations in the urine of patients with pancreatic cancer.
• New Chemotherapy Regimens for Pancreatic Cancer
• AACR: New Treatments Studied for Pancreatic Cancer –Doctors Lounge
  Targeting the hedgehog signaling pathway with a smoothened antagonist, GDC-0449, in combination with gemcitabine achieves partial response in some metastatic pancreatic cancer patients; and targeted depletion of the multi-functional cell membrane protein RLIP76 can cause pancreatic cancer tumors in mice to regress, according to two studies presented at the American Association for Cancer Research‘s Pancreatic Cancer: Progress and Challenges conference, held from June 18 to 21 in Lake Tahoe, Nev.
• RLIP76 contributes to pancreatic cancer cell resistance to chemotherapy and radiation | Science Codex
  Researchers at the City of Hope Comprehensive Cancer Center have not only identified a protein that allows pancreatic cancer cells to resist therapy but also developed a way to block it, according to results presented at the American Association for Cancer Research’s Pancreatic Cancer: Progress and Challenges conference, held here June 18-21.”Cancer of the pancreas is notoriously difficult to treat because it usually presents at late stages due to minimal or nonspecific symptoms in the early stages. Thus, surgical treatment is either not possible or fails to cure most patients, resulting in a dismal prognosis ? 90 percent of patients are likely to die within a year,” said Sanjay Awasthi, M.D., professor of medical oncology and therapeutics research, and diabetes, endocrinology and metabolism at City of Hope in Duarte, Calif.
• Metformin treatment caused cancer stem cell death in pancreatic cancer cell lines | Science Codex
  Results of some preclinical trials have shown that low doses of the antidiabetic drug metformin may effectively destroy cancer stem cells, a group of cells that are considered to be responsible for tumor initiation and, because they are resistant to standard chemotherapies, tumor relapse.In addition, when metformin was combined with a standard chemotherapy used for pancreatic cancer, the combination treatment was able to efficiently eradicate both cancer stem cells and more differentiated cancer cells, which form the bulk of the tumor, according to data presented by Christopher Heeschen, M.D., Ph.D., at the American Association for Cancer Research’s Pancreatic Cancer: Progress and Challenges conference, held in Lake Tahoe, Nev., from June 18-21, 2012. Heeschen is professor for experimental medicine at the Spanish National Cancer Research Centre in Madrid, Spain.
• Medical News: Pancreatic Ca Surgery Doable with Drug Combo – in Oncology/Hematology, Other Cancers from MedPage Today
  Four patients with unresectable pancreatic cancer had margin-negative surgery following treatment with a three-drug chemoradiation regimen, results of a small clinical trial showed.

Articles

Here are the latest additions to the Mendeley Pancreatic Cancer Genomics collection.

• Grape Proanthocyanidin Inhibit Pancreatic Cancer Cell Growth In Vitro and In Vivo through Induction of Apoptosis and by Targeting the PI3K/Akt Pathway
• Overexpressed Galectin-3 in Pancreatic Cancer Induces Cell Proliferation and Invasion by Binding Ras and Activating Ras Signaling
• Cdk4/6 Inhibition Induces Epithelial-Mesenchymal Transition and Enhances Invasiveness in Pancreatic Cancer Cells.
• MUC1 mucin stabilizes and activates hypoxia-inducible factor 1 alpha to regulate metabolism in pancreatic cancer.
• Molecular evidence for increased antitumor activity of gemcitabine in combination with a cyclin-dependent kinase inhibitor, P276-00 in pancreatic cancers.
• Role of heat shock protein 27 in gemcitabine-resistant human pancreatic cancer: Comparative proteomic analyses.
• INHIBITION OF THE HEDGEHOG PATHWAY TARGETS THE TUMOR-ASSOCIATED STROMA IN PANCREATIC CANCER.
• RhoT1 and Smad4 Are Correlated with Lymph Node Metastasis and Overall Survival in Pancreatic Cancer.
• Involvement of Host Stroma Cells and Tissue Fibrosis in Pancreatic Tumor Development in Transgenic Mice
• Involvement of Host Stroma Cells and Tissue Fibrosis in Pancreatic Tumor Development in Transgenic Mice
• Inactivation of Smad4 accelerates Kras(G12D)-mediated pancreatic neoplasia.
• Mutant KRAS in the initiation of pancreatic cancer.
• Sensitivity of BRCA2 mutated human cell lines to Aurora kinase inhibition.
• A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer.
• K-ras mutations in the plasma correspond to computed tomographic findings in patients with pancreatic cancer.
• Combination of hedgehog signaling blockage and chemotherapy leads to tumor reduction in pancreatic adenocarcinomas.
• ADAM9 expression in pancreatic cancer is associated with tumour type and is a prognostic factor in ductal adenocarcinoma.
• Circulating tumor cells in the diagnosis and management of pancreatic cancer.
• The Src family kinase inhibitors PP2 and PP1 effectively block TGF-beta1-induced cell migration and invasion in both established and primary carcinoma cells.
• H19-promoter-targeted therapy combined with gemcitabine in the treatment of pancreatic cancer.